GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome

By afschroeder • April 25, 2026

Wanner IB, Halford J, Lopez J, Shen S, Chen Y, Zhao H, Salas C, Loo RO, Robicsek S, Ellingson BM, Gornbein J, Van Meter TE, Shaw G, Loo JA, Vespa PM. GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome. Acta Neuropathol Commun. 2026 Apr 24;14(1):101. doi: 10.1186/s40478-026-02240-y. PMID: 42032706; PMCID: PMC13107622.

Tags: Astrocytopathy, Biomarker profiling, Citrullination, DOM STAT, General Internal Medicine, Monitoring, Neurodegeneration, Neurotrauma, Pathomechanism, proteostasis, Publications

Enhancing inpatient consultation workflow through implementation of an EHR direct-paging consult order system

Igawa T, Li-Fossum L, Zarrabi M, Kulkarni D, Lloyd J, Tseng B, Sim MS, McLitus M, Kozman DM, Ross MK. Enhancing inpatient consultation workflow through[...]

Childhood Sexual Abuse and Self-Reported Erectile Difficulties in Adult Men

Imanishi Y, Iorini M, Wada I, Jwa S, Tabuchi T, Uchida M. Childhood Sexual Abuse and Self-Reported Erectile Difficulties in Adult Men. Andrology. 2026 Apr[...]

Forearm BMD predicts fracture independently of FRAX

Kanis JA, Johansson H, Harvey NC, Lorentzon M, Cauley JA, Crandall CJ, Huisman M, Khosla S, Kwok T, Mellström D, Orwoll ES, van Schoor NM,[...]